[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 1962

Use of 5-Iodo-2′-Deoxyuridine (IDU) in Treatment of Herpes Simplex Keratitis

Author Affiliations

Gainesville, Fla.; Boston
Supported in part by Grants B 3538 and B 2220 from the National Institute of Neurological Diseases, and Blindness of the National Institutes of Health.

Arch Ophthalmol. 1962;68(2):235-239. doi:10.1001/archopht.1962.00960030239015

Herpes simplex infection of the cornea, unlike infection of the skin, tends to be chronic and to lead to opaque and blinding scars. A recent review of a large series of cases indicated that spontaneous clearing of herpetic keratitis within a reasonable period of time does not occur in more than 10% of cases. Temporary diminution of vision seems to be the rule, and "permanent diminution of vision was probably obtained in the majority of cases."1

Present therapy of herpes simplex keratitis consists primarily of the removal of infected tissue. When only the corneal epithelium is involved by the infection, removal of the area of ulcer seems to speed healing. This removal may be facilitated by the use of denaturing agents such as iodine or silver nitrate, by mechanical curettage, or by the use of enzymes such as chymotrypsin. Some of the agents which precipitate tissue protein also kill

First Page Preview View Large
First page PDF preview
First page PDF preview